Key result
Chemotherapy-primed sintilimab plus radiotherapy achieves ~28% tumor reduction in unresectable PAIS.
Why the study?
Pulmonary artery intimal sarcoma clinically and radiologically overlaps with pulmonary thromboembolism, and no standard systemic therapy exists for unresectable disease. Furthermore, although MDM2 amplification is the defining genomic event, it is usually treated as a supplementary finding rather than as a diagnostic test.
Case Report (n=1)
This case report highlights MDM2 amplification via next-generation sequencing as a decisive diagnostic anchor for pulmonary artery intimal sarcoma mimicking pulmonary embolism, and demonstrates 12.1-month progression-free survival using chemotherapy-primed PD-1 blockade and consolidative radiotherapy.
Answers are grounded in this paper and cite their sources.
MDM2 NGS may aid diagnosis of ambiguous pulmonary artery masses; leaves open multimodal therapy for unresectable intimal sarcoma.
Background Pulmonary artery intimal sarcoma (PAIS) is a rare and aggressive vascular malignancy whose clinical and radiological features overlap with those of pulmonary thromboembolism (PTE); most patients are initially anticoagulated, and no standard systemic therapy exists for unresectable disease. Amplification of MDM2 is the defining genomic event, yet it is usually treated as a supplementary finding rather than as a diagnostic test. Case presentation A 51-year-old man without thromboembolic risk factors presented with cough, sputum production, and chest discomfort. Contrast-enhanced computed tomography (CT) showed filling defects extending from the main pulmonary artery into both branches together with a 5.0 × 2.7 cm left upper lobe mass, and he received rivaroxaban until hemoptysis occurred. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT showed concordant hypermetabolism of the intravascular and parenchymal lesions. Two biopsies, including an expert review, narrowed the differential only to intimal sarcoma versus sarcomatoid carcinoma; next-generation sequencing then identified MDM2 amplification with CDKN2A deletion, a low tumor mutational burden (1.95 mutations/Mb), and negative PD-L1 expression, establishing MDM2-driven PAIS. Because the tumor was unresectable, he received six cycles of sintilimab, docetaxel, and cisplatin, two further cycles of sintilimab and docetaxel, consolidative intensity-modulated radiotherapy (60 Gy in 25 fractions), and maintenance sintilimab monotherapy. The best response was stable disease with a 27.9% reduction in the sum of target-lesion diameters, and progression-free survival reached 12.1 months without grade ≥3 immune-related adverse events. Conclusions When morphology and immunohistochemistry are indeterminate, MDM2 amplification can be the decisive diagnostic test rather than a supplementary finding, and it should be sought before empirical treatment is committed. Chemotherapy-primed PD-1 blockade followed by consolidative radiotherapy produced durable disease control in an immunologically cold tumor; prospective registries are needed to test this sequence.
No takes yet. Share an insight, caveat, or question.
Mou et al. (2026) conducted a case report in Unresectable pulmonary artery intimal sarcoma (PAIS) with MDM2 amplification (n=1). Sintilimab, docetaxel, and cisplatin followed by consolidative intensity-modulated radiotherapy and maintenance sintilimab was evaluated on Tumor response and progression-free survival. Chemotherapy-primed sintilimab and consolidative radiotherapy achieved a 27.9% target-lesion reduction and 12.1-month progression-free survival in unresectable MDM2-amplified PAIS.
Synapse has enriched 10 related papers. Consider them for comparative context: